NasdaqCM:NDRA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. More Details


Snowflake Analysis

Limited growth with imperfect balance sheet.

Share Price & News

How has ENDRA Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NDRA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.1%

NDRA

-0.8%

US Medical Equipment

-1.5%

US Market


1 Year Return

-48.8%

NDRA

15.2%

US Medical Equipment

12.9%

US Market

Return vs Industry: NDRA underperformed the US Medical Equipment industry which returned 15.2% over the past year.

Return vs Market: NDRA underperformed the US Market which returned 12.9% over the past year.


Shareholder returns

NDRAIndustryMarket
7 Day-4.1%-0.8%-1.5%
30 Day-19.0%1.2%-1.8%
90 Day-21.1%10.8%6.6%
1 Year-48.8%-48.8%16.2%15.2%15.4%12.9%
3 Year-75.9%-75.9%73.5%69.0%39.6%30.2%
5 Yearn/a158.1%138.5%93.4%71.7%

Price Volatility Vs. Market

How volatile is ENDRA Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ENDRA Life Sciences undervalued compared to its fair value and its price relative to the market?

12.75x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NDRA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NDRA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NDRA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: NDRA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NDRA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NDRA is overvalued based on its PB Ratio (12.7x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is ENDRA Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

6.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NDRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NDRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NDRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NDRA's revenue (160.9% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: NDRA's revenue (160.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NDRA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ENDRA Life Sciences performed over the past 5 years?

-47.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NDRA is currently unprofitable.

Growing Profit Margin: NDRA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NDRA is unprofitable, and losses have increased over the past 5 years at a rate of 47.6% per year.

Accelerating Growth: Unable to compare NDRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NDRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: NDRA has a negative Return on Equity (-1478.13%), as it is currently unprofitable.


Next Steps

Financial Health

How is ENDRA Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: NDRA's short term assets ($2.3M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: NDRA's short term assets ($2.3M) exceed its long term liabilities ($645.5K).


Debt to Equity History and Analysis

Debt Level: NDRA's debt to equity ratio (66.7%) is considered high.

Reducing Debt: Insufficient data to determine if NDRA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NDRA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NDRA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 44.5% each year


Next Steps

Dividend

What is ENDRA Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NDRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NDRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NDRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NDRA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NDRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average management tenure


CEO

Francois Michelon (54 yo)

5.17yrs

Tenure

US$978,776

Compensation

Mr. Francois Michelon has been the Chairman and Chief Executive Officer of ENDRA Life Sciences Inc. since July 2015 and has been its President. Mr. Michelon joined ENDRA in 2015. He has healthcare technolo ...


CEO Compensation Analysis

Compensation vs Market: Francois's total compensation ($USD978.78K) is above average for companies of similar size in the US market ($USD589.04K).

Compensation vs Earnings: Francois's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Francois Michelon
Chairman5.17yrsUS$978.78k0.39%
$ 62.3k
David Wells
CFO & Secretary6.67yrsUS$421.75k0.42%
$ 66.0k
Michael Thornton
Chief Technology Officer13.67yrsUS$808.61k0.94%
$ 149.6k
Jonathan Behr
Co-Founderno datano datano data
Steve Freeman
Human Resources Leader3.33yrsno datano data
Renaud Maloberti
Chief Commercial Officer1.33yrsno datano data

5.2yrs

Average Tenure

53yo

Average Age

Experienced Management: NDRA's management team is seasoned and experienced (5.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Francois Michelon
Chairman5.17yrsUS$978.78k0.39%
$ 62.3k
Anthony DiGiandomenico
Independent Director7.67yrsUS$259.13k1.62%
$ 256.9k
Alexander Tokman
Independent Director12.67yrsUS$259.13k0.068%
$ 10.8k
Michael Harsh
Independent Director5.17yrsUS$259.41k0.19%
$ 30.8k
Louis Basenese
Independent Director0.42yrno data0.34%
$ 54.1k
Jonathan Rubin
Scientific Advisor5.08yrsno datano data
Jing Gao
Scientific Advisorno datano datano data
Raza Malik
Scientific Advisor0.67yrno datano data

5.2yrs

Average Tenure

54yo

Average Age

Experienced Board: NDRA's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 182.4%.


Top Shareholders

Company Information

ENDRA Life Sciences Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ENDRA Life Sciences Inc.
  • Ticker: NDRA
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$15.880m
  • Shares outstanding: 20.96m
  • Website: https://www.endrainc.com

Number of Employees


Location

  • ENDRA Life Sciences Inc.
  • 3600 Green Court
  • Suite 350
  • Ann Arbor
  • Michigan
  • 48105
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NDRANasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2017

Biography

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technolo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/22 06:17
End of Day Share Price2020/09/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.